BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ding ZN, Dong ZR, Chen ZQ, Yang YF, Yan LJ, Li HC, Liu KX, Yao CY, Yan YC, Yang CC, Li T. Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis. J Gastroenterol Hepatol 2021;36:1487-96. [PMID: 33393670 DOI: 10.1111/jgh.15395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Reference Citation Analysis]
2 Fan C, Kam S, Ramadori P. Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. Cancers (Basel) 2021;13:5250. [PMID: 34680398 DOI: 10.3390/cancers13205250] [Reference Citation Analysis]
3 Kunadirek P, Ariyachet C, Sriphoosanaphan S, Pinjaroen N, Sirichindakul P, Nookaew I, Chuaypen N, Tangkijvanich P. Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Sci Rep 2021;11:11201. [PMID: 34045534 DOI: 10.1038/s41598-021-90515-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]